Compare Simon Property Group Inc (SPG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Simon Property Group Inc vs TG Therapeutics Inc — how do they compare? Simon Property Group Inc trades at $227 (market cap $74.00B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Simon Property Group Inc is far larger — about 9× TG Therapeutics Inc's market cap, and Simon Property Group Inc pays a 3.86% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SPG | TGTX | |
|---|---|---|
Market Cap | $74.00B | $8.26B |
Sector | Real Estate | Health |
52-Week High | $228.70 | $59.06 |
52-Week Low | $160.68 | $26.39 |
Enterprise Value | $102.48B | $8.50B |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPG trades at $226.79, down 0.84% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 earnings beating expectations at $1.48 per share versus $1.46 expected, continuing a pattern of earnings outperformance. Revenue growth has accelerated from $5.3B in 2022 to $6.4B in 2025, while net income surged to $4.63B with a remarkable 72.7% profit margin. Recent corporate developments include a $2.25 dividend payment and Euro-denominated note offering.
SPG presents a compelling investment case with strong operational performance and dividend yield exceeding 4%, though current valuation metrics suggest limited upside from analyst consensus targets. Key risks include high leverage with $24.21B long-term debt and sensitivity to interest rate movements. The stock's technical overbought condition near resistance levels warrants caution despite positive earnings momentum and institutional support.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
